ACE inhibitors or ARBs for diabetic nephropathy: The unrelenting debate

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 6, Issue 4, 2012, Pages 215-217

  Kota, Sunil K ^a   Meher, Lalit K ^b   Jammula, Sruti ^c   Kota, Siva K ^d   Modi, Kirtikumar D ^a  

^a Medwin Hospital   (India)

^b MKCG MEDICAL COLLEGE   (India)

^c ROLAND INSTITUTE OF PHARMACEUTICAL SCIENCES   (India)

^d Central Security Hospitals   (Saudi Arabia)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Diabetes mellitus

Indexed keywords

AMLODIPINE; CAPTOPRIL; IRBESARTAN; LOSARTAN; RAMIPRIL; TELMISARTAN;

ACUTE HEART INFARCTION; CARDIOVASCULAR SYSTEM; CLINICAL DECISION MAKING; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY; MICROALBUMINURIA; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84870423820     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2012.08.005     Document Type: Note

References (26)

1. G. Berrut, B. Bouhanick, P. Fabbri, G. Guilloteau, F. Bled, and J.J. Le Jeune Microalbuminuria as a predictor of a drop in glomerular filtration rate in subjects with non-insulin-dependent diabetes mellitus and hypertension Clinical Nephrology 48 1997 92 97 (Pubitemid 27371037)
2. W.F. Keane, B.M. Brenner, D. de Zeeuw, J.P. Grunfeld, J. McGill, and W.E. Mitch The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study Kidney International 63 2003 1499 1507 (Pubitemid 36350016)
3. D. de Zeeuw, G. Remuzzi, H.H. Parving, W.F. Keane, Z. Zhang, and S. Shahinfar Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy Circulation 110 2004 921 927 (Pubitemid 39128617)
4. H. Ibsen, K. Wachtell, M.H. Olsen, K. Borch-Johnsen, L.H. Lindholm, and C.E. Mogensen Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy Journal of Hypertension 22 2004 1805 1811 (Pubitemid 39141974)
5. B.M. Brenner, M.E. Cooper, D. de Zeeuw, W.F. Keane, W.E. Mitch, and H.H. Parving Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy New England Journal of Medicine 345 September 2001 861 869
6. H.H. Parving, H. Lehnert, J. Bröchner-Mortensen, R. Gomis, S. Andersen, and P. Arner The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes New England Journal of Medicine 345 2001 870 878
7. H. Ibsen, M.H. Olsen, K. Wachtell, K. Borch-Johnsen, L.H. Lindholm, and C.E. Mogensen Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study Hypertension 45 2005 198 202 (Pubitemid 40179960)
8. G.L. Bakris, M. Williams, L. Dworkin, W.J. Elliott, M. Epstein, and R. Toto Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group American Journal of Kidney Diseases 36 2000 646 661
9. H.H. Parving, A.R. Andersen, U.M. Smidt, and P.A. Svendsen Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy Lancet 1 1983 1175 1179 (Pubitemid 13092704)
10. E.J. Lewis, L.G. Hunsicker, R.P. Bain, and R.D. Rohde The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group New England Journal of Medicine 329 1993 1456 1462 (Pubitemid 23335891)
11. J.J. Parving, H. Lehnert, J. Brochner-Mortensen, R. Gomis, S. Andersen, P. Arner Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes New England Journal of Medicine 345 2001 870 878
12. G.D. Laverman, G. Navis, R.H. Henning, P.E. de Jong, and D. de Zeeuw Dual renin-angiotensin system blockade at optimal doses for proteinuria Kidney International 62 2002 1020 1025 (Pubitemid 35316733)
13. J.F. Mann, R.E. Schmieder, M. McQueen, L. Dyal, H. Schumacher, and J. Pogue Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 372 2008 547 553
14. A. Zanchetti, L. Hansson, B. Dahlöf, D. Elmfeldt, S. Kjeldsen, and R. Kolloch Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group Journal of Hypertension 19 2001 1149 1159 (Pubitemid 32493650)
15. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 317 1998 703 713
16. L. Niskanen, T. Hedner, L. Hansson, J. Lanke, A. Niklason, and CAPPP Study Group Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project Diabetes Care 24 2001 2091 2096 (Pubitemid 33716527)
17. Heart Outcomes Prevention Evaluation Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy Lancet 355 2000 253 259
18. L.H. Lindholm, H. Ibsen, B. Dahlöf, R.B. Devereux, G. Beevers, and U. de Faire Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 1004 1010 (Pubitemid 34286537)
19. T. Berl, L.G. Hunsicker, J.B. Lewis, M.A. Pfeffer, J.G. Porush, and J.L. Rouleau Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy Annals of Internal Medicine 138 2003 542 549
20. P. Tatti, M. Pahor, R.P. Byington, P. Di Mauro, R. Guarisco, and G. Strollo Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM Diabetes Care 21 1998 597 603 (Pubitemid 28172941)
21. K. Dickstein, J. Kjekshus, and OPTIMAAL Steering Committee of the OPTIMAAL Study Group Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan Lancet 360 2002 752 760 (Pubitemid 35247704)
22. M.A. Pfeffer, J.J. McMurray, E.J. Velazquez, J.L. Rouleau, L. Kober, and A.P. Maggioni Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both New England Journal of Medicine 349 2003 1893 1906 (Pubitemid 37409706)
23. J.J. McMurray, J. Ostergren, K. Swedberg, C.B. Granger, P. Held, and E.L. Michelson Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 2003 767 771 (Pubitemid 37093916)
24. F. Turnbull, and Blood Pressure Lowering Treatment Trialists' Collaboration Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials Lancet 362 2003 1527 1535 (Pubitemid 37410190)
25. G.F.M. Strippoli, M. Craig, P. Schena, and J.C. Craig Improved survival with ACE inhibitors compared with angiotensin II receptor antagonists in patients with diabetic nephropathy Journal of the American Society of Nephrology 14 2003 6A
26. E.J. Lewis, and J.B. Lewis ACE inhibitors versus angiotensin receptor blockers in diabetic nephropathy: is there a winner? Journal of the American Society of Nephrology 15 2004 1358 1360 (Pubitemid 38526020)